Investor Alert: Entheon Biomedical – Treating Addiction

Entheon is powered by an unwavering commitment to significantly improve the odds of beating addiction for people who otherwise might now

Entheon Biomedical is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N, N-dimethyltryptamine-based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders.

Entheon is researching and developing psychedelic drugs for the treatment of addiction disorders. With a focus on the psychedelic DMT molecule, Entheon’s upcoming human trial, EBRX-101 is one of the most comprehensive studies of DMT to date and will evaluate the pharmacodynamics, pharmacokinetics, and safety profile of DMT in order to advance it as a therapeutic for addiction disorder.

In addition, Entheon is focusing on the identification, analysis and predictive use of genetics and EEG biomarkers to develop a treatment system that personalizes patient care through all stages of the treatment continuum.

For more information on Entheon Biomedical Corp. (CSE: ENBI, OTCQB: ENTBF) please click the request investor info button.